Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
The human membralin (Mbrl) gene is located on chromosome 19, which has a high density GC and a rare repetitive DNA sequence. Mbrl is a highly conserved gene in the evolution of multiple species and is currently considered to be a tumor-associated marker.
Zhu et al. have shown that Mbrl is essential for maintaining the pathological state of Alzheimer's disease. Mbrl regulates the molecular machinery that produces beta-amyloid (Aβ) in cells – gamma secretase. If a molecule that regulates Mbrl can be found, or if it is determined to function in a cellular protein processing machinery, it may be able to inhibit neurodegeneration. Zhu et al. demonstrated that the Mbrl function is part of the ERAD system through proteomics, microscopic analysis and functional analysis. It was later discovered that the Mbrl-dependent ERAD decomposes a protein that is part of the γ-secretase complex, and that reducing Mbrl in Alzheimer's model mice exacerbates neurodegeneration and memory problems.

Figure 1. A schematic model of the ERAD component Mbrl in regulating nicastrin and Aβ generation. (Zhu, et al. 2017)
Expression of Mbrl
The current role of Mbrl is unclear, and it is expressed differently in different tissues. Andersson et al. found two splice variants in adult rat brain tissue, namely Mbrl-1 and Mbrl-2. In high-density neuronal regions, such as the cerebellar granule layer, the hippocampal CA1 and CA3 regions, and the dentate gyrus are highly expressed. In addition, these two splice variants are present in some non-neural tissues such as the choroid plexus, the renal medulla and the spleen. No expression was found in the thymus, lungs, heart, skeletal muscles and tongue. The human Mbrl gene has no homology with other human genes, but homologous genes or similar proteins can be found in other species. Mbrl is not closely related to other genes in the genome, suggesting that Mbrl may represent the only member of the family of proteins.
Mbrl and Tumor
The expression of Mbrl in different tissues and different parts of the same tissue suggests that it may be a new tumor marker. Mbrl is a highly conserved gene in the evolution of many species, and abnormal proliferation of Mbrl may lead to a variety of tumors. Studies have shown that long forms of Mbrl-1 and short forms of Mbrl-3 are found in ovarian cancer cell lines. The expression of Mbrl in normal ovarian epithelial and serous ovarian cancer was analyzed by PCR, in situ hybridization and Western blotting. It was found that Mbrl was highly expressed in tumor tissues of serous ovarian cancer, and normal ovarian epithelium was not expressed. The expression of serous ovarian cancer was significantly higher than that of solid ovarian cancer, but no hybridization signal was detected in stromal cells, endothelial cells and lymphocytes. The expression of Mbrl is positively correlated with the proliferation, invasion and response of chemotherapeutic drugs in serous ovarian cancer cells, and is a new tumor-associated marker for serous ovarian cancer.
In addition, Mbrl has also been found in breast, pancreatic and colorectal cancers. Studies have shown that Mbrl protein expression shows a strong-weak-strong change trend in each point of gastric cancer, indicating that Mbrl is involved in the invasion and metastasis of gastric cancer. These results suggest that Mbrl may be a tumor marker associated with tumor cell proliferation, invasion, and response to chemotherapy. Different Mbrl splices expressed differently in different tumors, and the same splice was also expressed differently in different tumors of the same tissue, suggesting that Mbrl is tissue-selectively expressed.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.